EBI-031 is under clinical development by Sesen Bio and currently in Phase II for Diabetic Macular Edema. According to GlobalData, Phase II drugs for Diabetic Macular Edema have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EBI-031’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RG-6179 (EBI-031) is under development for the treatment of diabetic macular edema (DME) and uveitis. The drug candidate is administered through intravitreal route. It is a humanized monoclonal antibody targeting interleukin-6. It is developed based on AMP-Rx protein engineering technology.
Sesen Bio overview
Sesen Bio (Sesen) is a late-stage clinical company that develops targeted fusion protein therapeutics (TFPTs) for the treatment of patients with cancer. The company’s TFPTs genetically combines targeting antibody fragments with cytotoxic protein payloads. Sesen’s product pipeline includes Vicinium (VB4-845) also known as oportuzumab monatox, which is used for the treatment of high-grade non-muscle invasive bladder cancer; and also, for the treatment of late-stage squamous cell carcinoma of the head and neck (SCHN). The company operates in the US, the UK, and Canada. Sesen is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of EBI-031’s drug-specific PTSR and LoA scores, buy the report here.